About Amryt

Leadership

Senior Management

Joe Wiley – CEO

Joe Wiley, CEO, founded Amryt and is a non-executive director of NASDAQ listed Innocoll AG. Mr. Wiley has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Mr Wiley opened and led Sofinnova Ventures' European office. He was previously a medical director at Astellas Pharma. Prior to joining Astellas, he held investment roles at Spirit Capital, Inventages Venture Capital and Aberdeen Asset Managers (UK).

Mr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He is also a Member of the Royal College of Physicians in Ireland and also has an MBA from INSEAD.

Rory Nealon – CFO/COO

Rory Nealon, CFO/COO, was previously a board member of Trinity Biotech Plc joining as Chief Financial Officer in January 2003. He was subsequently appointed Chief Operations Officer in November 2007. Mr Nealon left Trinity in 2014. Prior to joining Trinity Biotech Plc, he was Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland. Prior to joining Conduit he was an Associate Director in AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group.

Mr Nealon holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.

Mark Sumeray – CMO

Dr Sumeray has over 17 years’ experience in the pharmaceutical, medical devices and biotech sectors both in the US and UK. Most recently, he spent approximately five years as Chief Medical Officer at Aegerion Pharmaceuticals, a US-based orphan disease biotech company. At Aegerion, he had clinical development, medical affairs and pharmacovigilance responsibility for the global approval and launch of a new treatment for a serious and rare genetic disease. Mark led clinical and scientific interactions with health authorities globally, and engaged at senior level with the US Food and Drug Administration (“FDA”). His role also encompassed negotiations with payers and developing a market access strategy. In addition, Mark was the key company presenter at a Scientific Advice Group meeting of the Committee for Medicinal Products for Human Use (“CHMP”) in Europe.

Prior to working at Aegerion, Mark was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He also worked at The Medicines Company, a US based biopharmaceutical company focused on acute care hospital products, and at Ethicon, a J&J medical device company, where he was responsible for the clinical group.

Mark spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology, having qualified as a medical doctor at the University of London.

Michele Bellandi – Chief Commercial Officer

Mr Bellandi has over 20 years’ experience in the pharmaceuticals industry with a focus on specialty and rare diseases. He was most recently the Head of Commercial Europe for Shire where he was responsible for the entire portfolio representing over US$1 billion in revenues and 600 employees. He was previously General Manager of France, Spain and Portugal for the rare disease portfolio where he led multiple pricing negotiations of rare disease products. Prior to joining Shire AG International he was Global Marketing Director for the Neurology franchise at Merck Serono where he was responsible for Rebif and led the global launch preparation of oral Cladribine. Previously he worked with Eli Lilly & Company as Cymbalta Global Marketing Manager and in several other marketing/sales management roles in the US, Italy and Japan. Mr Bellandi holds a Masters in Economics from Pisa University and a Masters in Business Administration from CUOA Business School (Italy).

Dr Tobias Zahn – Head of Clinical Development

Dr Tobias Zahn joined Amryt as Head of Clinical Development in conjunction with the acquisition of Birken AG. Dr Zahn was previously Head of Pharmaceutical Development and Head of Sales and Business Development at Birken, where he joined the company in January 2009 and since 2011 was responsible for the development and successful European registration of the lead product Episalvan®. Prior to joining Birken, Dr Zahn was a consultant at The Boston Consulting Group.

Dr Zahn gained a PhD in cell biology from Witten/Herdecke University (Germany) and conducted research on diabetes in Denver, Colorado (USA) and Alzheimer’s disease in Dresden (Germany).

Email Alerts

Subscribe to Our Newsletter:

Delivered by Investis – link to website (opens in a new window)